Literature DB >> 23906297

Proteasome inhibition leads to altered signaling in the proteome of cisplatin-resistant human ovarian carcinoma cell line.

J Duraj, M Pastorek, J Vitkovska, D Cholujova, P Gronesova, L Hunakova, J Sedlak.   

Abstract

To address a precise view into molecular mechanisms of apoptotic signaling pathways after single- or combinatory treatments with specific NF-κB- or proteasome inhibitors and/or cisplatin (CDDP), flow cytometry and western blotting of the cell proteome in human ovarian chemosensitive- and CDDP-resistant cell lines were used. We report here that proteasome inhibition (but not NF-κB inhibition) caused marked alterations in the cell proliferation and cell cycle, as well as in the levels of signaling anti- and pro-apoptotic proteins PARP, NF-κB, IκB-α, Bcl-2, Bax, and lysosome-associated LAMP-1 and ATP-7B molecules in particular proteome fractions. These findings refer to the possibility of regulation of CDDP resistance, inclusive the capacity of lysosomes to export CDDP in certain human ovarian cancer cells by proteasome inhibition.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23906297     DOI: 10.4149/neo_2013_081

Source DB:  PubMed          Journal:  Neoplasma        ISSN: 0028-2685            Impact factor:   2.575


  3 in total

1.  Proteasome inhibitor MG132 inhibits the proliferation and promotes the cisplatin-induced apoptosis of human esophageal squamous cell carcinoma cells.

Authors:  Lifeng Dang; Fengbiao Wen; Yang Yang; Donglei Liu; Kai Wu; Yu Qi; Xiangnan Li; Jia Zhao; Dengyan Zhu; Chunyang Zhang; Song Zhao
Journal:  Int J Mol Med       Date:  2014-02-27       Impact factor: 4.101

2.  FXR agonists enhance the sensitivity of biliary tract cancer cells to cisplatin via SHP dependent inhibition of Bcl-xL expression.

Authors:  Wei Wang; Ming Zhan; Qi Li; Wei Chen; Huiling Chu; Qihong Huang; Zhaoyuan Hou; Mohan Man; Jian Wang
Journal:  Oncotarget       Date:  2016-06-07

3.  Cytoplasm-localized SIRT1 downregulation attenuates apoptosis and cell cycle arrest in cisplatin-resistant lung cancer A549 cells.

Authors:  Hyeran Yu; Young Mee Kim; Moonjae Cho
Journal:  J Cancer       Date:  2020-05-18       Impact factor: 4.207

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.